Pharmaceutical Drug Development Services Market: By Molecule Type (Biological Solutions, Small Molecule Solutions, and Biosimilar Development Solutions), By Phase (Pre-Clinical, Phase I, Phase II, Phase III), By Specialty Area (Cardiovascular, Diabetes, Endocrinology, Nephrology, Immuno-Oncology, Infectious Diseases, Oncology, Rare Diseases and Orphan Drugs, Pediatrics, Neuroscience, and Others) and Geography    

Purchase Option

$ 4400
$ 6600
$ 8900

Pharmaceutical Drug Development Services Market size was valued at USD x million in 2022 and is poised to grow at a  CAGR of x% from 2023 to 2029. Owing to increasing stringent regulatory framework and cost of drug development for products coupled with focus of the oxytocic pharmaceuticals and biopharmaceutical companies on CROs and CDMOs to reduce the cost of the development of the product are the major factors that are driving the growth of the pharmaceutical drug development services market. Moreover, Identification of lead, drug discovery, clinical trial monitoring and regulatory compliance fuels the growth of the market over the forecast period. This report studies global pharmaceutical drug development services market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global pharmaceutical drug development services market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global pharmaceutical drug development services market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).

Pharmaceutical Drug Development Services Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

x%

Largest Market

Asia-Pacific

Fastest Growing Market

North-America
Pharmaceutical Drug Development Services Market

The pharmaceutical and biopharmaceutical companies are focusing on the strategic collaborations with the drug development service providers to avoid the stringent regulatory policies and to reduce the cost of the drug development and this is the trend that was being observed in the market. For instance, in June 2018, Syneos Health and Elligo Health Research entered into a strategic collaboration to mobilize a system of accelerated research to reach real-world patients.

Pharmaceutical Drug Development Services Market Segmentation

By Molecule Type
  • Biologic Solutions
  • Small Molecule Solutions
  • Biosimilar Development Solutions
By Phase
  • Pre-Clinical
  • Phase I
  • Phase II
  • Phase III
By Specialty Area
  • Cardiovascular
  • Diabetes, Endocrinology, and Nephrology
  • Immuno-Oncology
  • Infectious Diseases
  • Oncology
  • Rare Diseases and Orphan Drugs
  • Pediatrics
  • Neuroscience
  • Others

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • Global pharmaceutical drug development services market expanding at significant CAGR over 2023 to 2029 owing to increasing demand for outsourcing to the CROs and CDMOs for drug development services.
  • Based on specialty area, oncology segment of pharmaceutical drug development services accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
  • Players focusing on collaboration strategies with the government to retain market position in global pharmaceutical drug development services market
1. Executive Summary
2. Global Pharmaceutical Drug Development Services Market Introduction
2.1. Global Pharmaceutical Drug Development Services Market – Taxonomy
2.2. Global Pharmaceutical Drug Development Services Market – Definitions
2.2.1. By Molecule
2.2.2. By Phase
2.2.3. By Specialty Type
3. Global Pharmaceutical Drug Development Services Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Pharmaceutical Drug Development Services Market Dynamics – Factors Impact Analysis
4. Global Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Pharmaceutical Drug Development Services Market Forecast, By Molecule, 2018 - 2022 and Forecast, 2023 - 2029
5.1. Biologic Solutions
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Small Molecule Solutions
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Biosimilar Development Solutions
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Pharmaceutical Drug Development Services Market Forecast, By Phase, 2018 - 2022 and Forecast, 2023 - 2029
6.1. Pre-Clinical
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Phase 1
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Phase II
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Phase III
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Pharmaceutical Drug Development Services Market Forecast, By Specialty Type, 2018 - 2022 and Forecast, 2023 - 2029
7.1. Cardiovascular
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Diabetes, Endocrinology, and Nephrology
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Immuno-Oncology
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Infectious Diseases
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Oncology
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Rare Diseases and Orphan Drugs
7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Pediatrics
7.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Neuroscience
7.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
7.9. Others
7.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.9.3. Market Opportunity Analysis
8. Global Pharmaceutical Drug Development Services Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. The Middle East & Africa
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Product, By Application, By End User, and Region, 2023 - 2029
9. North America Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
9.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Biologic Solutions
9.1.2. Small Molecule Solutions
9.1.3. Biosimilar Development Solutions
9.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Pre-Clinical
9.2.2. Phase I
9.2.3. Phase II
9.2.4. Phase III
9.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Cardiovascular
9.3.2. Diabetes, Endocrinology, and Nephrology
9.3.3. Immuno-Oncology
9.3.4. Infectious Diseases
9.3.5. Oncology
9.3.6. Rare Diseases and Orphan Drugs
9.3.7. Pediatrics
9.3.8. Neuroscience
9.3.9. Others
9.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule Type, By Phase, By Specialty Type, and Country, 2023 - 2029
9.6. North America Pharmaceutical Drug Development Services Market Dynamics – Trends
10. Europe Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
10.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Biologic Solutions
10.1.2. Small Molecule Solutions
10.1.3. Biosimilar Development Solutions
10.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Pre-Clinical
10.2.2. Phase I
10.2.3. Phase II
10.2.4. Phase III
10.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Cardiovascular
10.3.2. Diabetes, Endocrinology, and Nephrology
10.3.3. Immuno-Oncology
10.3.4. Infectious Diseases
10.3.5. Oncology
10.3.6. Rare Diseases and Orphan Drugs
10.3.7. Pediatrics
10.3.8. Neuroscience
10.3.9. Others
10.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029
10.6. Europe Pharmaceutical Drug Development Services Market Dynamics – Trends
11. Asia Pacific Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
11.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Biologic Solutions
11.1.2. Small Molecule Solutions
11.1.3. Biosimilar Development Solutions
11.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Pre-Clinical
11.2.2. Phase I
11.2.3. Phase II
11.2.4. Phase III
11.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Cardiovascular
11.3.2. Diabetes, Endocrinology, and Nephrology
11.3.3. Immuno-Oncology
11.3.4. Infectious Diseases
11.3.5. Oncology
11.3.6. Rare Diseases and Orphan Drugs
11.3.7. Pediatrics
11.3.8. Neuroscience
11.3.9. Others
11.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. ASEAN Counties
11.4.5. Philippines
11.4.6. Rest of Asia Pacific
11.5. Asia Pacific Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029
11.6. Asia Pacific Pharmaceutical Drug Development Services Market Dynamics – Trends
12. Latin America Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
12.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Biologic Solutions
12.1.2. Small Molecule Solutions
12.1.3. Biosimilar Development Solutions
12.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Pre-Clinical
12.2.2. Phase I
12.2.3. Phase II
12.2.4. Phase III
12.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Cardiovascular
12.3.2. Diabetes, Endocrinology, and Nephrology
12.3.3. Immuno-Oncology
12.3.4. Infectious Diseases
12.3.5. Oncology
12.3.6. Rare Diseases and Orphan Drugs
12.3.7. Pediatrics
12.3.8. Neuroscience
12.3.9. Others
12.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Mexico
12.4.2. Brazil
12.4.3. Argentina
12.4.4. Chile
12.4.5. Rest of Latin America
12.5. Latin America Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029
12.6. Latin America Pharmaceutical Drug Development Services Market Dynamics – Trends
13. Middle East and Africa Pharmaceutical Drug Development Services Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
13.1. Molecule Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Biologic Solutions
13.1.2. Small Molecule Solutions
13.1.3. Biosimilar Development Solutions
13.2. Phase Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Pre-Clinical
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.3. Specialty Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Cardiovascular
13.3.2. Diabetes, Endocrinology, and Nephrology
13.3.3. Immuno-Oncology
13.3.4. Infectious Diseases
13.3.5. Oncology
13.3.6. Rare Diseases and Orphan Drugs
13.3.7. Pediatrics
13.3.8. Neuroscience
13.3.9. Others
13.4. Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Saudi Arabia
13.4.4. Turkey
13.4.5. Rest of MEA
13.5. Middle East & Africa Pharmaceutical Drug Development Services Market - Opportunity Analysis Index, By Molecule, By Phase, By Specialty Type, and Country, 2023 - 2029
13.6. Middle East & Africa Pharmaceutical Drug Development Services Market Dynamics – Trends
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Company Profiles (Includes Company Overview, Business Description, Financials, SWOT Analysis, and Strategic Developments)
15. Assumptions and Acronyms Used
16. Research Methodology
  • Syneos Health
  • Parexel
  • IQVIA
  • Celerion
  • Piramal Pharma solutions
  • Catalent, Inc.
  • Patheon – a Thermo Fisher Company
  • Pharmaceutical Product Development, LLC.
  • Covance Inc.
  • MEDPACE

Adjacent Markets